TRexBio logo

TRexBio Employee Directory

Biotechnology ResearchCalifornia, United States51-200 Employees

TRexBio is a clinical-stage biotechnology company focused on discovering and developing immunoregulatory medicines based on tissue regulatory T cell biology. It emphasizes human tissue biology and uses computational biology tools as part of its Deep Biology platform to map tissue Treg behavior to disease processes and identify therapeutic targets. Its lead program, TRB-061, is a TNFR2-selective agonist in a Phase 1 trial for atopic dermatitis, designed to activate and expand effector Tregs in tissue to restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California, and employs about 51 to 200 people. The company has pursued collaborations and financing rounds, including a 2023 multi-year research collaboration with Eli Lilly and a Series B financing in 2024 (including an oversubscribed round of $84 million), with a $50 million extension announced in 2026.

Find TRexBio employees' phone numbers or email addresses

TRexBio Global Highlights

Location
Employees

North America
66

Minus sign iconPlus sign icon
  • United States Of America
    66

Oceania
1

Minus sign iconPlus sign icon
  • Australia
    1

TRexBio's Leadership

  • Chief Operating Officer at TRexBio
    L. B.
    Chief Operating Officer
  • Vice President And Head Of Translational Medicine at TRexBio
    M. T.
    Vice President And Head Of Translational Medicine
  • Associate Director, Clinical Operations at TRexBio
    K. S.
    Associate Director, Clinical Operations
  • Project Manager at TRexBio
    A. L.
    Project Manager
  • Senior Scientist at TRexBio
    J. A. C.
    Senior Scientist
  • Principal Scientist at TRexBio
    J. V.
    Principal Scientist
  • Senior Scientist at TRexBio
    J. G.
    Senior Scientist
  • Associate Scientist Ii at TRexBio
    S. D.
    Associate Scientist Ii

TRexBio Employee Metrics

100%
50%
0%
2026
2025
  • Research
  • Biotechnology
  • Operations
  • Administrative
  • Human Resources
  • Other
  • Business
  • Entrepreneurship
  • Community & Social Services
  • Consultant

Contact profiles from TRexBio

Name
Title
Contact
Location
Last Update
  • Scientist I In Discovery at TRexBio
    C. L.
    Scientist I In Discovery
    Bay
    Jul 10, 2026
  • Research Scientist at TRexBio
    J. D. L. C.
    Research Scientist
    Oct 17, 2024
  • Clinical Trial Liaison at TRexBio
    R. G.
    Clinical Trial Liaison
    Australia, Victoria
    Jun 11, 2026
  • Associate Scientist Ii, Translational Biology at TRexBio
    C. N.
    Associate Scientist Ii, Translational Biology
    Bay
    Aug 18, 2026
  • Employee at TRexBio
    H. Y.
    Jul 20, 2023

Frequently Asked Questions

What is TRexBio known for?

Minus sign iconPlus sign icon
TRexBio was founded in 2018 and operates in the Biotechnology Research industry. Explore TRexBio's company overview page for more information.

What is TRexBio's most common email format?

Minus sign iconPlus sign icon
TRexBio employees' email format typically follows the pattern of FLast@trex.bio. Trying to find reliable and up-to-date employee contact data? Find more TRexBio email formats with LeadIQ.

How many employees does TRexBio have currently?

Minus sign iconPlus sign icon
TRexBio has approximately 62 employees as of August 2026. These team members are located across 2 continents, including North America and Oceania.

Who are TRexBio's key employees and leadership?

Minus sign iconPlus sign icon

As of August 2026, TRexBio's key employees include:

  • Chief Operating Officer: L. B.
  • Vice President And Head Of Translational Medicine: M. T.
  • Associate Director, Clinical Operations: K. S.
  • Project Manager: A. L.
  • Senior Scientist: J. A. C.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.